Posted On: Sep-2026 | Categories : Healthcare
Precision oncology is transforming cancer treatment by shifting therapeutic decisions from broad disease classifications toward molecularly defined treatment strategies based on genomic alterations, biomarkers, immune characteristics, and tumor-expressed antigens. The approach focuses on identifying the biological mechanisms responsible for tumor growth and matching patients with therapies designed around those specific molecular features. Biomarkers are increasingly used not only for diagnosis but also to predict treatment response, monitor disease progression, and guide therapeutic selection.
The traditional model of oncology treatment was largely based on tumor location, histology, and disease stage. However, advances in molecular profiling have demonstrated that cancers originating from the same organ can represent biologically different diseases. A patient with lung cancer, breast cancer, ovarian cancer, or prostate cancer may now follow a completely different treatment pathway depending on whether their tumor carries EGFR mutations, HER2 expression, BRCA alterations, KRAS mutations, MSI-high status, or other clinically relevant molecular characteristics.
This transition has changed the structure of oncology drug development. Pharmaceutical companies are increasingly focusing on smaller, biomarker-defined patient populations where treatment mechanisms can be matched with specific disease drivers. Targeted small molecules, antibody-drug conjugates (ADCs), immune-based therapies, protein degraders, and other precision platforms are expanding beyond conventional chemotherapy approaches by addressing specific molecular vulnerabilities within cancer cells.
The commercial importance of precision oncology is increasing alongside clinical adoption. Oncology remains one of the largest areas of pharmaceutical innovation, with global oncology medicine spending reaching approximately $252 billion in 2024 as targeted therapies, immunotherapies, cell therapies, and molecularly guided treatment approaches continue expanding. The oncology pipeline is also becoming increasingly concentrated around biologically defined patient populations, creating demand for molecular diagnostics, sequencing platforms, clinical data systems, and companion diagnostic technologies.
Precision oncology is therefore developing as an integrated healthcare ecosystem rather than a standalone drug category. The success of a targeted therapy increasingly depends on the ability to identify eligible patients, interpret molecular results accurately, and connect diagnostic information with treatment decisions.
The growth of precision oncology depends on one critical capability: identifying which patients carry molecular characteristics that can influence treatment response. As therapies become increasingly targeted, biomarker testing has shifted from an additional diagnostic option to an essential component of oncology decision-making.
The expansion of molecular profiling has significantly increased the number of patients who may benefit from targeted treatments. Analysis of more than 47,000 tumor samples showed that the proportion of tumors carrying potentially treatable genomic biomarkers increased from 8.9% in 2017 to 31.6% within five years, reflecting the rapid expansion of actionable targets across cancer types.
However, clinical implementation remains a major challenge. While comprehensive genomic profiling can identify potential treatment opportunities in a substantial proportion of advanced cancers, access to testing and matched therapies remains inconsistent. Approximately 32% to 39% of advanced cancer patients receive recommended molecular or biomarker testing, creating a gap between the availability of precision therapies and their real-world utilization.
This gap represents one of the largest opportunities in precision oncology. The next phase of market development is not only focused on discovering new biomarkers but also improving testing adoption, reimbursement coverage, clinical interpretation, and integration of molecular results into routine oncology workflows.
Non-small cell lung cancer (NSCLC) has become the most established example of biomarker-driven cancer treatment. Over the last decade, NSCLC management has shifted from broad chemotherapy-based approaches toward molecular classification, where treatment selection depends on identifying specific driver alterations.
Biomarker testing rates for established targets in NSCLC approach 95% in advanced healthcare settings, making lung cancer one of the most mature precision oncology applications. The disease has effectively transformed from a single treatment category into multiple molecularly defined subgroups, including EGFR-mutated, ALK-positive, ROS1-positive, KRAS G12C-driven, MET-altered, RET-positive, and NTRK-positive cancers.
This molecular segmentation has created separate therapeutic pathways and expanded the opportunity for targeted drug development. EGFR mutations enable treatment with EGFR tyrosine kinase inhibitors, ALK rearrangements allow use of ALK-targeted therapies, KRAS G12C alterations have created a new class of mutation-specific inhibitors, and RET or ROS1 alterations provide opportunities for selective kinase inhibition.
The clinical impact of this approach is reflected in improved outcomes among biomarker-selected patients. Studies evaluating molecularly matched treatment approaches have demonstrated higher response rates compared with non-personalized strategies, with precision therapy groups achieving response rates above 30% compared with approximately 4.9% in non-matched treatment groups. Other analyses have reported median progression-free survival of approximately 5.7 months with precision-guided treatment compared with 2.95 months for conventional approaches, although outcomes vary depending on cancer type, biomarker strength, and therapy availability.
The diagnostic infrastructure supporting NSCLC precision treatment has expanded rapidly. Foundation Medicine has developed comprehensive genomic profiling platforms such as FoundationOne CDx that identify multiple clinically relevant alterations and support targeted therapy selection. Guardant Health has expanded blood-based genomic testing through circulating tumor DNA approaches that enable mutation detection without requiring traditional tissue samples. Thermo Fisher Scientific has strengthened oncology testing capabilities through sequencing technologies and companion diagnostic solutions.
Despite strong adoption, implementation gaps remain. Real-world studies indicate that NGS adoption in NSCLC varies approximately between 46% and 63% depending on healthcare networks, showing that guideline recommendations have not yet translated into uniform testing access across all clinical settings.
Recent regulatory developments continue expanding the NSCLC precision oncology landscape, with new therapies targeting resistant alterations such as EGFR exon 20 insertions, ROS1 rearrangements, and other molecular drivers reinforcing the importance of comprehensive biomarker testing.
Breast and ovarian cancers have become major areas of precision oncology adoption because biomarker testing directly influences therapy selection. Genetic and predictive biomarker testing rates in these cancers are approximately 80%, supported by established clinical guidelines and the availability of multiple targeted treatment options.
HER2 remains one of the most important biomarkers in oncology because it has continuously expanded the therapeutic landscape. Initially, HER2 testing was primarily used to identify patients eligible for HER2-positive breast cancer therapies. However, the emergence of the HER2-low breast cancer category has expanded the role of HER2 assessment by identifying additional patients who may benefit from HER2-directed antibody-drug conjugates.
The development of HER2-targeted ADCs demonstrates how improved biomarker classification can create new treatment categories within existing cancer populations. Roche has played a major role in HER2 diagnostics and targeted oncology treatments, while AstraZeneca and Daiichi Sankyo have expanded HER2-directed treatment approaches through trastuzumab deruxtecan.
In ovarian cancer, molecular testing has become increasingly important because BRCA1/2 mutations and homologous recombination deficiency (HRD) status influence eligibility for PARP inhibitor therapies. The integration of genetic testing has shifted ovarian cancer management beyond clinical staging toward molecular risk assessment, enabling physicians to identify patients more likely to benefit from targeted DNA repair pathway therapies.
Prostate cancer is increasingly adopting precision oncology approaches, particularly in advanced disease where molecular characteristics influence treatment selection. Biomarker testing adoption is approximately 75%, with growing attention toward DNA repair alterations, BRCA1/2 mutations, homologous recombination repair defects, and PSMA expression.
The emergence of PARP inhibitors has increased the importance of identifying patients with DNA damage repair abnormalities, while PSMA-targeted radiopharmaceutical therapies have created another precision treatment pathway based on tumor antigen expression.
The clinical significance of molecular testing is expanding because advanced prostate cancer treatment is no longer determined only by hormone sensitivity or disease progression. Genetic and molecular information increasingly influences the selection of targeted therapies and radioligand approaches.
Companies such as Novartis have advanced PSMA-targeted radiopharmaceutical therapies, while pharmaceutical developers continue expanding treatment options for genetically defined prostate cancer populations.
The expansion of precision oncology has created demand for diagnostic platforms capable of identifying multiple molecular alterations from limited patient samples. Early biomarker testing often focused on individual mutations, but clinical practice is increasingly moving toward comprehensive genomic profiling that evaluates multiple genes simultaneously.
Next-generation sequencing, liquid biopsy, RNA profiling, whole-exome sequencing, and companion diagnostic technologies are becoming essential components of oncology care. Companies including Foundation Medicine, Guardant Health, Tempus, and Caris Life Sciences are developing platforms that combine genomic information with clinical data to support treatment decisions.
The ecosystem is also expanding beyond major US and European markets. Companies such as 4baseCare are working to increase access to comprehensive genomic profiling in emerging healthcare systems through NGS-based testing approaches designed for routine oncology practice. Recent collaborations with hospitals in India are focused on integrating large-scale genomic profiling into clinical workflows and improving affordability of precision cancer testing.
Precision oncology is entering a new phase where single-gene mutation analysis is being replaced by integrated tumor profiling approaches that combine multiple biological data layers. While next-generation sequencing (NGS) has transformed cancer classification by identifying actionable mutations, DNA alterations alone often fail to capture tumor evolution, immune interactions, and mechanisms responsible for treatment resistance.
Multiomic profiling combines genomics, transcriptomics, proteomics, epigenomics, metabolomics, and spatial biology to provide a more complete representation of tumor behavior. This shift is commercially important because pharmaceutical companies and diagnostic developers are increasingly using broader biological datasets to identify new therapeutic targets, improve patient selection, and increase clinical trial success rates.
Transcriptomic and proteomic profiling are becoming increasingly valuable in cancers where genetic alterations do not fully predict treatment response. By analyzing RNA activity and protein expression patterns, researchers can identify biological pathways driving tumor progression and determine why certain patients respond differently to the same therapy.
Spatial biology is emerging as a major precision oncology technology area because conventional sequencing cannot fully explain tumor heterogeneity. Spatial transcriptomics and spatial proteomics allow researchers to map tumor cells, immune cells, and surrounding tissue interactions, creating new opportunities to understand immune escape, drug resistance, and response to immunotherapies.
Companies such as 10x Genomics and Bruker are advancing spatial and single-cell analysis platforms, while pharmaceutical companies are incorporating multiomic datasets into drug discovery pipelines and biomarker-driven clinical trials. The integration of AI is further accelerating this transition by combining genomic, pathology, imaging, and clinical datasets. Multiomic AI models have demonstrated AUC performance of approximately 0.81–0.87 in early cancer detection and classification applications, highlighting their potential in improving patient stratification and treatment decision-making.
The growth of precision oncology is increasingly driven by the expansion of actionable biomarkers that transform broad cancer populations into smaller, treatment-defined patient groups. Each validated biomarker creates commercial opportunities across targeted therapies, companion diagnostics, and specialized treatment pathways.
Early precision oncology strategies focused primarily on established biomarkers such as HER2, EGFR, ALK, and BRCA. However, the market is expanding toward more complex molecular drivers, including ESR1 mutations, KRAS alterations, RAS pathway changes, DNA repair deficiencies, and tumor-specific antigens.
This biomarker expansion is reshaping pharmaceutical development models. Drug developers are increasingly designing therapies for genetically defined patient populations rather than relying only on traditional cancer classifications, improving the probability of identifying responsive patient groups.
Recent precision oncology developments during 2025–2026 have increasingly focused on previously difficult targets and treatment-resistant disease mechanisms, including selective estrogen receptor degraders, protein degraders, next-generation kinase inhibitors, bispecific antibodies, and pathway-specific inhibitors. This trend is expanding the precision oncology ecosystem beyond sequencing toward integrated platforms combining diagnostics, biomarker discovery, AI analytics, and targeted therapeutics.
Recent approvals demonstrate how precision oncology is expanding beyond conventional targeted therapy categories.
Resistance to endocrine therapy remains a major challenge in hormone receptor-positive breast cancer. ESR1 mutations are one of the key mechanisms associated with acquired resistance after treatment with endocrine therapies.
Selective estrogen receptor degraders (SERDs) and next-generation estrogen receptor-targeting approaches are being developed to address this challenge.
Imlunestrant (Inluriyo) represents this shift by targeting ESR1-mutated estrogen receptor-positive, HER2-negative advanced breast cancer. The therapy works by binding to estrogen receptors and promoting receptor degradation, reducing estrogen-driven tumor signaling.
Another emerging approach is Vepdegestrant (Veppanu), a PROTAC-based estrogen receptor degrader. Unlike conventional inhibitors that block receptor activity, PROTAC technology aims to remove disease-driving proteins by directing them toward cellular degradation pathways.
These therapies demonstrate the broader movement in precision oncology from blocking biological pathways toward eliminating specific disease-associated proteins.
RAS mutations have historically represented one of the most challenging targets in oncology because of the complexity of the RAS signaling pathway. However, advances in molecular understanding have led to the development of direct RAS inhibitors and emerging molecular glue approaches.
Daraxonrasib (Rasonque) represents a newer approach targeting RAS-mutated cancers, including metastatic pancreatic cancer. The development of direct RAS inhibitors highlights how precision oncology is increasingly addressing historically difficult molecular drivers.
Beyond direct inhibitors, companies are exploring molecular glue technologies designed to alter protein interactions and selectively disrupt oncogenic signaling pathways. ERAS-0015, developed by Erasca, represents research efforts focused on targeting RAS/MAPK pathway alterations through novel mechanisms.
The importance of RAS-targeted innovation extends beyond individual therapies because RAS mutations occur across multiple cancers, including pancreatic, colorectal, and lung cancers.
Antibody-drug conjugates (ADCs) have become one of the most important therapeutic platforms within precision oncology because they combine molecular targeting with highly potent drug delivery.
ADCs consist of three major components: a tumor-targeting antibody, a chemical linker, and a cytotoxic payload. The antibody identifies cancer cells expressing a specific antigen, allowing delivery of the payload directly to tumor tissue.
The success of HER2-directed ADCs has accelerated investment into additional ADC targets, including:
HER2
Trop-2
Nectin-4
Folate receptor alpha
CD30
CD33
The expansion of ADCs demonstrates how biomarker refinement can increase the addressable patient population for targeted therapies. The emergence of HER2-low breast cancer is a key example, where improved molecular classification created a new treatment opportunity for patients who previously had limited HER2-directed options.
Companies including Daiichi Sankyo, AstraZeneca, Pfizer, and Seagen are investing heavily in ADC platforms. Pfizer’s acquisition of Seagen strengthened its oncology portfolio by adding established ADC technologies and expanding capabilities in targeted cancer therapies.
The growth of ADCs is also creating opportunities in manufacturing. Because ADC production requires specialized conjugation, containment, and analytical capabilities, companies such as Lonza and Samsung Biologics are expanding biologics and ADC manufacturing capabilities.
Bispecific antibodies represent another rapidly expanding precision oncology platform. Unlike conventional antibodies that bind to a single target, bispecific antibodies are designed to interact with two different biological targets simultaneously.
Many oncology bispecific antibodies are designed to connect cancer cells with immune cells, particularly T cells, enabling targeted immune activation against tumors.
This approach has shown significant progress in hematological malignancies, with increasing research focus on extending applications into solid tumors.
Companies including Amgen and Roche are developing bispecific antibody platforms targeting different cancer pathways.
The growing interest in bispecific antibodies reflects the broader trend of combining molecular targeting with immune system activation rather than relying on direct tumor killing alone.
Precision oncology is increasingly moving toward therapies that exploit unique vulnerabilities within cancer cells.
Protein degraders, including PROTACs and molecular glue technologies, represent a new therapeutic approach where the objective is not only to inhibit disease-driving proteins but to remove them completely from cancer cells.
This approach has attracted significant investment because many cancer-associated proteins were historically considered difficult or impossible to target.
Synthetic lethality represents another important strategy. These therapies exploit situations where cancer cells become dependent on specific biological pathways because of existing mutations.
PARP inhibitors represent one of the most successful examples, targeting tumors with BRCA mutations or homologous recombination repair deficiencies.
Emerging approaches include:
WRN inhibitors targeting MSI-high tumors
POLθ inhibitors targeting DNA repair vulnerabilities
Additional DNA damage response inhibitors
Companies such as IDEAYA Biosciences are developing synthetic lethality approaches designed around specific genetic vulnerabilities, while Relay Therapeutics uses computational and structural biology approaches to identify difficult drug targets.
The future precision oncology pipeline is increasingly focused on overcoming treatment resistance and addressing targets that were previously inaccessible.
Emerging areas include:
Direct RAS inhibition
Molecular glues
Protein degradation
Antibody-targeted therapy conjugates
Tumor antigen targeting
Synthetic lethality approaches
These platforms reflect a broader change in oncology drug development. The objective is no longer only to discover drugs that slow tumor growth, but to identify specific biological weaknesses that can be selectively exploited.
The next phase of precision oncology is moving beyond identifying the right therapy before treatment initiation toward continuously monitoring how tumors evolve during therapy. Liquid biopsy has become one of the most important technologies supporting this transition because it enables molecular analysis through blood samples rather than relying only on repeated tissue biopsies.
Liquid biopsy evaluates cancer-derived materials circulating in the bloodstream, particularly circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs). These molecular signals provide information about tumor genetics, treatment response, emerging resistance mechanisms, and residual disease after therapy.
The clinical importance of liquid biopsy is increasing because cancer is not a static disease. Tumors evolve under treatment pressure, and genetic alterations that were absent at diagnosis may emerge later and drive resistance. Traditional tissue biopsies provide information from a specific location and time point, whereas liquid biopsy offers the possibility of repeated monitoring throughout the treatment journey.
In advanced lung cancer, liquid biopsy is increasingly used to identify actionable mutations when tissue samples are insufficient or unavailable. In patients receiving targeted therapies, circulating tumor DNA analysis can help detect resistance mutations and guide subsequent treatment decisions.
Companies such as Guardant Health have expanded liquid biopsy applications through platforms such as Guardant360 CDx, which supports genomic profiling for treatment selection. The company has also developed Guardant Reveal for detecting minimal residual disease signals in certain cancer settings. Natera has advanced the use of ctDNA monitoring through its Signatera platform, which is being evaluated for recurrence monitoring across multiple cancer types.
The commercial importance of liquid biopsy extends beyond diagnostics. As precision oncology therapies become more numerous, the ability to monitor treatment response and identify resistance early is becoming a critical component of personalized cancer management.
The expansion of biomarker-driven therapies has created a stronger connection between pharmaceutical development and diagnostic technologies. Companion diagnostics are becoming an essential component of precision oncology because they determine whether a patient carries the molecular characteristics required for a specific therapy.
A targeted therapy without a reliable diagnostic pathway limits the ability of clinicians to identify eligible patients. As a result, pharmaceutical companies increasingly develop drugs alongside diagnostic tests that can demonstrate biomarker status during clinical development and after approval.
Examples include:
HER2 testing for HER2-directed therapies and ADCs
BRCA and HRD testing for PARP inhibitors
PD-L1 testing for immune checkpoint inhibitors
EGFR, ALK, ROS1, and KRAS testing for targeted lung cancer therapies
The companion diagnostics ecosystem has expanded through collaborations between pharmaceutical companies and diagnostic developers. Roche has maintained a strong position through its combined diagnostics and oncology capabilities, allowing integration between biomarker testing and targeted treatment development.
Qiagen, Agilent Technologies, Thermo Fisher Scientific, and other diagnostic companies continue developing molecular testing platforms that support oncology drug adoption.
The growing importance of companion diagnostics is also changing pharmaceutical economics. Drug developers are increasingly required to consider the entire treatment pathway, including patient identification, diagnostic accessibility, and clinical implementation, rather than focusing only on therapeutic development.
Artificial intelligence is increasingly being integrated into precision oncology because modern cancer care generates extremely large volumes of biological and clinical information. Genomic sequencing data, pathology images, radiology scans, electronic health records, and treatment outcomes create complex datasets that are difficult to analyze using traditional methods.
AI is being applied across multiple stages of the oncology pathway, including cancer detection, molecular classification, biomarker discovery, treatment selection, and clinical trial recruitment.
In diagnostic imaging, AI-supported tools are improving cancer detection workflows. Studies evaluating AI-assisted lung cancer screening have reported sensitivity levels above 90% for detecting pulmonary nodules, while AI-supported approaches have demonstrated reductions in false-positive findings in certain screening settings.
AI is also expanding the capabilities of digital pathology. Traditional pathology relies heavily on expert interpretation of tissue samples, but AI models can analyze large numbers of pathology images to identify patterns associated with tumor classification, biomarker expression, and treatment response.
In molecular oncology, AI platforms are being developed to identify relationships between genomic alterations and clinical outcomes. Integrated models combining genomics, radiomics, and transcriptomics have demonstrated AUC values of approximately 0.81 to 0.87 in complex cancer prediction applications.
Companies such as Tempus are building AI-powered platforms that combine clinical records, molecular profiles, and treatment data to support oncology decision-making. PathAI focuses on AI-powered pathology solutions, while Paige develops AI tools designed to improve cancer diagnosis and biomarker assessment.
The role of AI in precision oncology is expected to expand as healthcare systems improve their ability to integrate genomic information, pathology data, imaging, and real-world clinical outcomes.
Precision oncology is no longer limited to pharmaceutical companies. The field now includes diagnostics companies, sequencing providers, AI companies, biotechnology firms, and specialized manufacturing organizations.
Foundation Medicine has become one of the most recognized companies in comprehensive genomic profiling, supporting biomarker identification and therapy selection through broad cancer sequencing platforms.
Guardant Health has expanded liquid biopsy adoption by developing blood-based genomic testing solutions for treatment selection and disease monitoring.
Tempus has built a large clinical and molecular data ecosystem combining genomic information, patient records, and artificial intelligence to support personalized treatment decisions.
Caris Life Sciences has focused on comprehensive molecular profiling using genomic and transcriptomic approaches to characterize tumors beyond DNA mutations alone.
The pharmaceutical landscape is increasingly shaped by companies developing targeted therapies for molecularly defined patient groups.
AstraZeneca has expanded its oncology portfolio through targeted therapies, immunotherapy, and ADC platforms.
Daiichi Sankyo has become a major player in ADC development, particularly through HER2-directed approaches.
Roche combines oncology therapeutics with diagnostic capabilities, providing an integrated approach to biomarker-driven cancer care.
Novartis has expanded precision oncology applications through targeted therapies and radiopharmaceutical approaches.
Smaller biotechnology companies are also contributing to innovation. IDEAYA Biosciences focuses on synthetic lethality approaches, while Relay Therapeutics applies computational biology to identify difficult drug targets.
Despite significant progress, precision oncology adoption continues to face several challenges that influence clinical implementation.
One major challenge is the gap between biomarker discovery and real-world testing. Although thousands of molecular alterations can be identified through comprehensive genomic profiling, not every alteration has an approved therapy or sufficient clinical evidence to support treatment decisions.
The actionability gap remains significant. Comprehensive genomic profiling may identify potential treatment-relevant alterations in many patients, but actual access to matched therapies is influenced by reimbursement, clinical trial availability, regulatory approval, and healthcare infrastructure.
Another challenge is unequal access to molecular testing. Academic cancer centers often have greater access to genomic testing and multidisciplinary molecular tumor boards compared with community oncology settings. Studies indicate that more than 70% of community-treated lung cancer patients may not receive complete guideline-recommended biomarker testing, highlighting differences in precision oncology implementation.
Data integration is another important limitation. Precision oncology requires coordination between:
Genomic testing
Pathology
Imaging
Electronic health records
Clinical outcomes
Without effective data integration, clinicians may struggle to convert molecular information into actionable treatment decisions.
Precision oncology is moving from mutation identification toward continuous treatment optimization, where multiomic profiling, liquid biopsy, and AI-based interpretation are expected to improve patient selection and monitor emerging resistance mechanisms during therapy. The growing adoption of ADCs, protein degraders, molecular glues, and synthetic lethality approaches reflects a shift toward targeting specific biological vulnerabilities rather than treating cancers only by tumor origin. Future growth will depend on how effectively healthcare systems integrate advanced diagnostics with targeted therapies to reduce testing gaps and expand access to biomarker-driven treatment pathways.